Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20048699rdf:typepubmed:Citationlld:pubmed
pubmed-article:20048699lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:20048699lifeskim:mentionsumls-concept:C0037791lld:lifeskim
pubmed-article:20048699pubmed:issue5lld:pubmed
pubmed-article:20048699pubmed:dateCreated2010-1-5lld:pubmed
pubmed-article:20048699pubmed:abstractTextEffective vaccine-elicited immunity against HIV-1 infection will likely require broadly neutralizing antibodies to interrupt the fusion-promoting functions of the viral envelope glycoprotein spikes. Efforts in this area have, however, been fraught with challenges. The handful of existing broadly neutralizing monoclonal antibodies has provided information on some of the virus' sites of vulnerability, fueling a decade of structure-informed vaccine design. The fact that very few bnmAbs have been recovered to date illustrates the poor immunogenicity of these epitopes. Recognizing that progress may require more basic information, there has been a notable shift in the field toward identifying new chinks in HIV-1's armor. These efforts are based on the observation that some infected patients develop exceptionally broad serum neutralizing antibodies responses, a better understanding of which would be valuable for vaccine efforts aimed at eliciting similar specificities.lld:pubmed
pubmed-article:20048699pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20048699pubmed:languageenglld:pubmed
pubmed-article:20048699pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20048699pubmed:citationSubsetIMlld:pubmed
pubmed-article:20048699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20048699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20048699pubmed:statusMEDLINElld:pubmed
pubmed-article:20048699pubmed:monthSeplld:pubmed
pubmed-article:20048699pubmed:issn1746-6318lld:pubmed
pubmed-article:20048699pubmed:authorpubmed-author:BinleyJamesJlld:pubmed
pubmed-article:20048699pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20048699pubmed:volume4lld:pubmed
pubmed-article:20048699pubmed:ownerNLMlld:pubmed
pubmed-article:20048699pubmed:authorsCompleteYlld:pubmed
pubmed-article:20048699pubmed:pagination364-72lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:meshHeadingpubmed-meshheading:20048699...lld:pubmed
pubmed-article:20048699pubmed:year2009lld:pubmed
pubmed-article:20048699pubmed:articleTitleSpecificities of broadly neutralizing anti-HIV-1 sera.lld:pubmed
pubmed-article:20048699pubmed:affiliationTorrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California, USA. jbinley@tpims.orglld:pubmed
pubmed-article:20048699pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20048699pubmed:publicationTypeReviewlld:pubmed
pubmed-article:20048699pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20048699pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20048699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20048699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20048699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20048699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20048699lld:pubmed